• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Exelixis

Graphic image of a pen signing a signature while two strangelooking business people cheer
Biotech

Merck inks Keytruda supply pact to support Exelixis cancer trial

Securing supplies of subcutaneous Keytruda completes the trio of contributors needed to run the colorectal cancer trial.
Nick Paul Taylor May 19, 2026 9:38am
Lifeline

Midsize biotechs form coalition to fight against MFN policy

Feb 25, 2026 1:05pm
Morrissey
Favicon Fierce Pharma

Exelixis aims to be a top 5 solid tumor drugmaker in the US: CEO

Jan 16, 2026 1:00pm
reshuffle pipeline target reorganize shift change

ESMO: Exelixis' TKI reduces risk of death by 20%

Oct 20, 2025 2:30am
Job cuts employee layoffs firings or downsizing Scissors dividing individuals positioned on colorful blocks

Exelixis plans shuttering of East Coast site, 130 layoffs

Aug 29, 2025 9:15am
Graphic image of an arrow nailing the bullseye of a target

Exelixis beats Bayer drug in cancer trial, sending stock higher

Jun 23, 2025 7:30am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings